ProQR Therapeutics N.V

PRQRNASDAQ · USD
1.66USD0.00 (+0.61%)
135

ProQR Therapeutics N.V (PRQR) Option Chain

As of September 30, 2026, ProQR Therapeutics N.V is trading at $1.66, a +0.61% change from the previous close. The nearest expiration is Oct 16, 2026. Implied volatility is 216.7%. IV Rank is 30%.

Read more

Tracking the PRQR option chain helps you see every strike and expiry on ProQR Therapeutics N.V in one view, so you can quickly identify the contracts that fit your thesis and your risk. ProQR Therapeutics N.V's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of PRQR options activity at a glance. Use our scanner to monitor the PRQR option chain in real time and filter for the PRQR options trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For PRQR stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the PRQR option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where PRQR stock options are being actively traded and where they are not.

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system.

ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls ProQR Therapeutics N.V's full chain across every expiry, highlights the most liquid strikes, and lets you screen PRQR options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of PRQR stock options — let the full option chain come to you, pre-filtered and ready to trade.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile35.71% Neutral
  • Market cap (M$)229
  • 52 weeks high-46.45%
  • 52 weeks low24.81%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$8.87
    434.34% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-05
  • P/E—
  • Future P/E—
  • EPS (ttm)-0.46
  • EPS growth next 5 years-6.55%

As of September 30, 2026

2026-10-16
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
0.72000.041.160.701.700.50-69.88—1.000.001.000099.28
18.2210-0.110.660.051.051.00-39.76—0.100.000.100081.78
49.813140.390.16—0.551.50-9.64—0.200.000.200050.19
73.741,26500.150.00—0.152.00+20.480.051.050.340.210026.26
87.121,45460.100.00—0.102.50+50.60—0.900.840.060112.88

As of September 30, 2026

Scan the full option chain in one place

Browse the full PRQR option chain across every strike and expiration, filter by IV, volume, and open interest, and evaluate your trade without switching tools.

Start your 14-day free trial